BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 17112805)

  • 1. Impact of P-glycoprotein on clopidogrel absorption.
    Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
    Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
    von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
    Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
    Yi SY; Hong KS; Lim HS; Chung JY; Oh DS; Kim JR; Jung HR; Cho JY; Yu KS; Jang IJ; Shin SG
    Clin Pharmacol Ther; 2004 Nov; 76(5):418-27. PubMed ID: 15536457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
    Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
    Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking behaviour modulates pharmacokinetics of orally administered clopidogrel.
    Yousef AM; Arafat T; Bulatova NR; Al-Zumyli R
    J Clin Pharm Ther; 2008 Aug; 33(4):439-49. PubMed ID: 18613862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
    Jaitner J; Morath T; Byrne RA; Braun S; Gebhard D; Bernlochner I; Schulz S; Mehilli J; Schömig A; Koch W; Kastrati A; Sibbing D
    Circ Cardiovasc Interv; 2012 Feb; 5(1):82-8, S1-2. PubMed ID: 22298798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
    Johne A; Köpke K; Gerloff T; Mai I; Rietbrock S; Meisel C; Hoffmeyer S; Kerb R; Fromm MF; Brinkmann U; Eichelbaum M; Brockmöller J; Cascorbi I; Roots I
    Clin Pharmacol Ther; 2002 Nov; 72(5):584-94. PubMed ID: 12426522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
    Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.
    Pauli-Magnus C; Feiner J; Brett C; Lin E; Kroetz DL
    Clin Pharmacol Ther; 2003 Nov; 74(5):487-98. PubMed ID: 14586389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets.
    Zafar MU; Farkouh ME; Fuster V; Chesebro JH
    J Interv Cardiol; 2009 Aug; 22(4):385-9. PubMed ID: 19496900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta.
    Rahi M; Heikkinen T; Hakkola J; Hakala K; Wallerman O; Wadelius M; Wadelius C; Laine K
    Hum Exp Toxicol; 2008 Jan; 27(1):65-71. PubMed ID: 18480151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs.
    Lassoued MA; Sfar S; Bouraoui A; Khemiss F
    J Pharm Pharmacol; 2012 Apr; 64(4):541-52. PubMed ID: 22420660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
    Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
    Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study.
    L'Allier PL; Ducrocq G; Pranno N; Noble S; Ibrahim R; Grégoire JC; Azzari F; Nozza A; Berry C; Doucet S; Labarthe B; Théroux P; Tardif JC;
    J Am Coll Cardiol; 2008 Mar; 51(11):1066-72. PubMed ID: 18342223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of clopidogrel.
    Caplain H; Donat F; Gaud C; Necciari J
    Semin Thromb Hemost; 1999; 25 Suppl 2():25-8. PubMed ID: 10440419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
    Verstuyft C; Strabach S; El-Morabet H; Kerb R; Brinkmann U; Dubert L; Jaillon P; Funck-Brentano C; Trugnan G; Becquemont L
    Clin Pharmacol Ther; 2003 Jan; 73(1):51-60. PubMed ID: 12545143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
    Kharasch ED; Hoffer C; Altuntas TG; Whittington D
    J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.